KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.

The KRAS oncogene, present in over 90% of pancreatic ductal adenocarcinomas, is most frequently the result of one of three gain-of-function substitution mutations of codon 12 glycine. Thus far, RAS mutations have been clinically refractory to both direct and selective inhibition by systemic therapeu...

書目詳細資料
發表在:	PLoS ONE
Main Authors:	Donald D Rao, Xiuquan Luo, Zhaohui Wang, Christopher M Jay, Francis C Brunicardi, William Maltese, Luisa Manning, Neil Senzer, John Nemunaitis
格式:	Article
語言:	英语
出版:	Public Library of Science (PLoS) 2018-01-01
在線閱讀:	http://europepmc.org/articles/PMC5979018?pdf=render

相似書籍

A pan-KRAS degrader for the treatment of KRAS-mutant cancers
由: Jie Yang, et al.
出版: (2024-06-01)

MICA ∗012:01 Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer
由: Weifeng Ding, et al.
出版: (2020-05-01)

Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization
由: Kohei Maruyama, et al.
出版: (2025-01-01)

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers
由: Man Yan, et al.
出版: (2026-04-01)

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
由: Alessandro Tubita, et al.
出版: (2025-09-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
由: Satoru Miyazaki, et al.
出版: (2025-02-01)

Exploring KRas Protein Dynamics: An Integrated Molecular Dynamics Analysis of KRas Wild and Mutant Variants
由: Showkat Ahmad Mir, et al.
出版: (2024-07-01)

Role of silent mutations in KRAS-mutant tumors
由: Jun Lu, et al.
出版: (2025-02-01)

Small molecular inhibitors for KRAS-mutant cancers
由: Xuan Wu, et al.
出版: (2023-08-01)

In silico analysis of wild-type and mutant KRAS
由: Frengki Frengki, et al.
出版: (2019-05-01)

Structural modifications and kinetic effects of KRAS interactions with HRAS and NRAS: an in silico comparative analysis of KRAS mutants
由: Isaac Silverman, et al.
出版: (2024-08-01)

Functional analysis of ESM1 by shRNA-mediated knockdown of its expression in papillary thyroid cancer cells
由: Lijun Xie, et al.
出版: (2024-01-01)

Intranasal delivery of shRNA to knockdown the 5HT-2A receptor enhances memory and alleviates anxiety
由: Troy T. Rohn, et al.
出版: (2024-03-01)

PRMT5 Inhibition as a Potential Strategy for KRAS Mutant CRC: Downstream Mediators of the PRMT5–KRAS Crosstalk
由: Mark Spivak, et al.
出版: (2025-08-01)

Computational screening of phytochemicals targeting mutant KRAS in colorectal cancer
由: Muskan Arooj, et al.
出版: (2025-08-01)

Oncogenic mutant KRAS inhibition through oxidation at cysteine 118
由: Maximilian Kramer‐Drauberg, et al.
出版: (2025-02-01)

Research progress in the related treatment of KRAS mutant colorectal cancer
由: ZHANG Shaohua, LI Zhening, WANG Wei, WEI Yifan, HONG Yonggang, HAO Liqiang
出版: (2024-10-01)

Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
由: Patrícia Dias Carvalho, et al.
出版: (2022-06-01)

Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment
由: Ranjan Preet, PhD, et al.
出版: (2018-01-01)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
由: Xin Dai, et al.
出版: (2015-01-01)

Analyzing efficiency of a lentiviral shRNA knockdown system in human enteroids using western blot and flow cytometry
由: Adam P. Wilson, et al.
出版: (2024-06-01)

Marijan Kraš
由: Andrea Toljan, et al.
出版: (2023-11-01)

shRNA‑mediated knockdown of KNTC1 inhibits non-small-cell lung cancer through regulating PSMB8
由: Ruijun Liu, et al.
出版: (2022-08-01)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
由: Sara Costa-Cabral, et al.
出版: (2016-01-01)

Targeting Mutant <i>KRAS</i> in Pancreatic Cancer: Futile or Promising?
由: Friederike Inga Nollmann, et al.
出版: (2020-08-01)

Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcome
由: Dan Zhao, et al.
出版: (2024-06-01)

Therapeutic Approach of KRAS Mutant Tumours by the Combination of Pharmacologic Ascorbate and Chloroquine
由: Orsolya Kapuy, et al.
出版: (2021-04-01)

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
由: Haitang Yang, et al.
出版: (2019-09-01)

Ultrasonic Microbubble Cavitation Deliver Gal-3 shRNA to Inhibit Myocardial Fibrosis after Myocardial Infarction
由: Wenqu Li, et al.
出版: (2023-02-01)

AURKA/PHB2 signaling drives acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant NSCLC
由: Jinrong Liao, et al.
出版: (2026-04-01)

Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform
由: Matteo Rossi, et al.
出版: (2023-12-01)

Knockdown of CREB3/Luman by shRNA in Mouse Granulosa Cells Results in Decreased Estradiol and Progesterone Synthesis and Promotes Cell Proliferation.
由: Fan Zhao, et al.
出版: (2016-01-01)

Induction of fetal hemoglobin: Lentiviral shRNA knockdown of HBS1L in β0-thalassemia/HbE erythroid cells.
由: Sukanya Chumchuen, et al.
出版: (2023-01-01)

Optimized Multiplex Detection of 7 KRAS Mutations by Taqman Allele-Specific qPCR.
由: Andrea Orue, et al.
出版: (2016-01-01)

Allele-specific KRAS signaling: shaping tumor immunity and therapeutic response in lung adenocarcinoma
由: Kostas A. Papavassiliou, et al.
出版: (2026-05-01)

Metformin combined with CB-839 specifically inhibits KRAS-mutant ovarian cancer
由: Han Wu, et al.
出版: (2025-02-01)

Metabolomic Approach to Identify Potential Biomarkers in KRAS-Mutant Pancreatic Cancer Cells
由: Boyun Kim, et al.
出版: (2024-04-01)

Down-Regulation of AKT Proteins Slows the Growth of Mutant-KRAS Pancreatic Tumors
由: Chuankai Chen, et al.
出版: (2024-06-01)

Novel insights into the RTK-dependent metastatic phenotype of KRAS-mutant lung adenocarcinoma
由: Mariana Cooke
出版: (2021-11-01)

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study
由: Fan Yang, et al.
出版: (2024-01-01)